Iovance Biotherapeutics, Inc. (IOVA) — 10-Q Filings
All 10-Q filings from Iovance Biotherapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Iovance Revenue Surges, But Restructuring Costs Widen Losses
— Nov 6, 2025 Risk: high
Iovance Biotherapeutics, Inc. reported a significant increase in product revenue, reaching $67.455 million for the three months ended September 30, 2025, up fro -
IOVA's Q2 Net Loss Widens Amid R&D Surge for Amtagvi
— Aug 7, 2025 Risk: high
IOVANCE BIOTHERAPEUTICS, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net -
IOVANCE BIOTHERAPEUTICS Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
IOVANCE BIOTHERAPEUTICS, INC. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Lion Biotechnologies, Inc., reported financial -
IOVANCE BIOTHERAPEUTICS Files Q3 2024 10-Q
— Nov 7, 2024 Risk: medium
IOVANCE BIOTHERAPEUTICS, INC. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Lion Biotechnologies, Inc., is focused on -
IOVANCE BIOTHERAPEUTICS Files Q2 2024 10-Q
— Aug 8, 2024 Risk: low
IOVANCE BIOTHERAPEUTICS, INC. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Lion Biotechnologies, Inc., is focused on biolo -
IOVA Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. IOVA filed a 10-Q report for the period ending March 31, 2024.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX